Non-U.S. Clinical Trials & Regulatory Actions: April 2013

May 2013
BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p24
A table is presented on the Non-U.S. Clinical Trials & Regulatory Actions as of April, 2013 which lists pharmaceutical products of several pharmaceutical companies including Celgene Corp. for cancer, Avanir Pharmaceuticals Inc. for central nervous system, and Medivir AB for injection.


Related Articles

  • Avanir Drug Candidate Advances to 2nd-Phase Trial. Reed, Vila // Orange County Business Journal;10/15/2012, Vol. 35 Issue 42, p28 

    No abstract available.

  • Avanir Publishes Phase III Data For Neuropathic Pain Combo. Shaffer, Catherine // BioWorld Today;2/9/2012, Vol. 23 Issue 18, p2 

    This article reports on the positive results of a Phase III efficacy trial of Avanir Pharmaceuticals Inc.'s AVP-923, which is a combination of cough medicine dextromethorphan and antiarrhythmic agent quinidine, for diabetic neuropathic pain. The combination of dextromethorphan and quinidine is...

  • Avanir Shares Triple On Zenvia Phase III Results.  // Bioworld Week;4/23/2007, Vol. 15 Issue 17, p5 

    The article reports that the stock rates of Avanir Pharmaceuticals Inc. has increased after the company announced positive top-line data from a phase III trial of Zenvia in diabetic neuropathic pain in the U.S. According to the said company, the initial efficacy and safety data from the...

  • Avanir Cutting Costs, Exploring Options To Fund Zenvia Work. Boggs, Jennifer // BioWorld Today;3/30/2007, Vol. 18 Issue 62, p1 

    The article reports on the plan of Avanir Pharmaceuticals Inc. to cut costs and explore options to fund the study of Zenvia. Zenvia is an approvable product for involuntary emotional expression disorder. The company expects to reduce its annual operation costs to $20 million, and hopes to add...

  • Avanir commences Phase II Alzheimer's study.  // PharmaWatch: CNS;Nov2012, Vol. 11 Issue 11, p8 

    The article reports on the move by Avanir Pharmaceuticals, Inc. to start the Phase II clinical trial on the effectiveness of AVP-923 for the treatment of agitation in patients with Alzheimer's disease (AD). The multicenter, randomized, double-blind, placebo-controlled study is due to enroll as...

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;March 2004, Vol. 3 Issue 3, p2 

    Reports developments related to the biotechnology industry in the U.S. as of March 2004. Failure of the clinical trial of Repifermin for the treatment of cancer therapy-induced mucositis by the Human Genome Sciences; Partnership between Avanir Pharmaceuticals Inc. and VaxGen; Result of the...

  • CLINIC ROUNDUP.  // BioWorld Today;12/13/2013, Vol. 24 Issue 239, p10 

    The article offers clinical trials news briefs as of December 2013 including Medivir AB's open label trial of combination therapy of simeprevir, TMC647055 and JNJ56914845, PTC Therapeutics' trial of ataluren and the joint venture of Rainbow Coral and Therakine for a new drug delivery technology.

  • Medivir Financial Statement, 1 Jan - 31 March 2011.  // Biomedical Market Newsletter;5/9/2011, p349 

    The article offers information on the financial results and business update of Medivir AB, for the first quarter of 2011. According to the chief executive officer (CEO) of the company, Ron Long, their lead project TMC435, a next generation protease inhibitor for hepatitis C, has resulted...

  • Medivir: TMC649128 enters Phase Ib Trial in Patients Chronically Infected with Genotype-1 Hepatitis C Virus.  // Biomedical Market Newsletter;6/30/2011, p467 

    The article reports on the TMC649128 Phase Ib clinical trial started by Medivir AB, which aimed for the treatment of chronic hepatitis C virus (HCV) infection in Huddinge, Sweden. It mentions that the study is used to evaluate safety, tolerability and pharmacokinetics of multiple ascending doses...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics